Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study-Reference-Cited by-同舟云学术

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

Published:2012-07 Issue:7 Volume:20 Page:1426-1436
ISSN:1930-7381
Container-title:Obesity
language:en
Short-container-title:

Author:

O'Neil Patrick M.,Smith Steven R.,Weissman Neil J.,Fidler Meredith C.,Sanchez Matilde,Zhang Jinkun,Raether Brian,Anderson Christen M.,Shanahan William R.

Publisher

Wiley

Subject

Nutrition and Dietetics,Endocrinology,Endocrinology, Diabetes and Metabolism,Medicine (miscellaneous)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1038/oby.2012.66/fullpdf

Reference32 articles.

1. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity;Halford;Drugs,2007

2. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis;Xu;Neuron,2008

3. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways;Zhou;Cell Metab,2007

4. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women;Smith;Obesity (Silver Spring),2009

5. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure;Martin;J Clin Endocrinol Metab,2011

Cited by 452 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weight Management and Metabolic Surgery;Textbook of Diabetes;2024-01-12

2. Adipose tissue inflammation linked to obesity: A review of current understanding, therapies and relevance of phyto-therapeutics;Heliyon;2024-01

3. The Use of Phentermine for Obesity in Psychiatric Patients With Antipsychotics;Psychiatry Investigation;2023-09-25

4. Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity;European Journal of Preventive Cardiology;2023-08-30

5. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial;The Lancet;2023-08